Dae W. Jun

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 305 publications

Alcohol-Aware Risk Stratification and Subtype-Specific Care Pathways Across MASLD, MetALD, and ALD.

Alcohol-Aware Risk Stratification and Subtype-Specific Care Pathways Across MASLD, MetALD, and ALD.

Journal: Clinical and molecular hepatology

Published: May 27, 2026

Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.

Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.

Journal: Gut

Published: April 16, 2026

Correction to: Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes.

Correction to: Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes.

Journal: Gut and liver

Published: March 16, 2026

The MASLD Journey in the General Population: Linkage-to-Care and Patient-Reported Uptake of Fibrosis Risk Assessment.

The MASLD Journey in the General Population: Linkage-to-Care and Patient-Reported Uptake of Fibrosis Risk Assessment.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: March 01, 2026

The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on "Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations".

The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on "Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations".

Journal: Clinical and molecular hepatology

Published: January 28, 2026

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Journal: Clinical and molecular hepatology

Published: January 20, 2026

Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Journal: Clinical and molecular hepatology

Published: January 13, 2026

Polygenic Risk Score Predicts Prognosis in Nonobese Metabolic Dysfunction-Associated Steatotic Liver Disease but not in Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: A Multicenter Cohort Study.

Polygenic Risk Score Predicts Prognosis in Nonobese Metabolic Dysfunction-Associated Steatotic Liver Disease but not in Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: A Multicenter Cohort Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 22, 2025

Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.

Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.

Journal: The American journal of gastroenterology

Published: October 13, 2025

Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis.

Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis.

Journal: The American journal of gastroenterology

Published: October 13, 2025

Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort.

Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 25, 2025

Allyl nonanoate as a novel bile-derived biomarker in metabolic dysfunction-associated steatotic liver disease.

Allyl nonanoate as a novel bile-derived biomarker in metabolic dysfunction-associated steatotic liver disease.

Journal: Frontiers in endocrinology

Published: September 17, 2025

Showing 1-12 of 305

Last Updated: 09/26/2026